|
Issue |
Title |
|
Vol 2, No 1 (2022) |
A brief report of real-world evidence development (RWD/RWE) in 2021: United States, Russia, and the Eurasian Economic Union (EAEU) |
Abstract
PDF (Rus)
PDF (Eng)
|
A. S. Kolbin, D. Yu. Belousov |
|
Vol 1, No 1 (2021) |
Applying real-world data to justify requirements to purchased drugs in public procurement |
Abstract
PDF (Rus)
PDF (0,3 Mb) (Eng)
|
M. A. Borzova |
|
Vol 2, No 1 (2022) |
Aspects of the safe use of medicinal products based on medicinal plant materials in COVID-19 |
Abstract
PDF (Rus)
|
A. A. Taube |
|
Vol 2, No 1 (2022) |
Chinese experience on using RWE to support drug research, development and evaluation |
Abstract
PDF (Rus)
|
A. S. Kolbin, D. Yu. Belousov |
|
Vol 1, No 1 (2021) |
Paracetamol safety in COVID-19 |
Abstract
PDF (Rus)
PDF (0,2 Mb) (Eng)
|
B. K. Romanov |
|
Vol 2, No 1 (2022) |
Power BI as an auxiliary tool for biostatistics |
Abstract
PDF (Rus)
|
N. Yu. Dmitrieva |
|
Vol 2, No 1 (2022) |
Real-world data: general regulatory approaches in the EU and Japan |
Abstract
PDF (Rus)
PDF (Eng)
|
M. A. Borzova |
|
Vol 2, No 1 (2022) |
Real-world evidence market: key players and key segments |
Abstract
PDF (Rus)
|
A. R. Kasimova, A. S. Kolbin |
|
Vol 1, No 1 (2021) |
Registers as the basis for data collection and evidence building |
Abstract
PDF (Rus)
PDF (0,3 Mb) (Eng)
|
A. V. Ivanov |
|
Vol 1, No 1 (2021) |
Resolution based on the results of the conference: "RWD/ RWE – Research Tools of Real-World Clinical Practice Today and Tomorrow" |
Abstract
PDF (Rus)
PDF (0,2 Mb) (Eng)
|
A. S. Kolbin |
|
Vol 1, No 1 (2021) |
Why do we need "Real-World Data & Evidence", the new scientific electronic journal? |
Abstract
PDF (0,34 Мб) (Rus)
PDF (0,3 Mb) (Eng)
|
A. S. Kolbin |
|
1 - 11 of 11 Items |
|